Search
Search Results
-
The HSP90 inhibitor KW-2478 depletes the malignancy of BCR/ABL and overcomes the imatinib-resistance caused by BCR/ABL amplification
BackgroundWith the widespread clinical application of tyrosine kinase inhibitors (TKIs), an increasing number of chronic myeloid leukaemia (CML)...
-
Small-molecule inhibitor targeting the Hsp70-Bim protein–protein interaction in CML cells overcomes BCR-ABL-independent TKI resistance
Herein, we screened a novel inhibitor of the Hsp70-Bim protein-protein interaction (PPI), S1g-2 , from a Bcl-2 inhibitor library; this compound...
-
Deubiquitylase USP25 prevents degradation of BCR-ABL protein and ensures proliferation of Ph-positive leukemia cells
Fusion genes resulting from chromosomal rearrangements are frequently found in a variety of cancer cells. Some of these are known to be driver...
-
Role of miRNAs to control the progression of Chronic Myeloid Leukemia by their expression levels
Chronic Myeloid Leukemia (CML) is a myeloproliferative disorder distinguished by a specific genetic anomaly known as a reciprocal translocation...
-
State-transition modeling of blood transcriptome predicts disease evolution and treatment response in chronic myeloid leukemia
Chronic myeloid leukemia (CML) is initiated and maintained by BCR::ABL which is clinically targeted using tyrosine kinase inhibitors (TKIs). TKIs can...
-
Target spectrum of the BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia
BCR-ABL1 plays a key role in the pathogenesis of chronic myeloid leukemia (CML), and it has been investigated as a druggable target of tyrosine...
-
Naked antisense double-stranded DNA oligonucleotide efficiently suppresses BCR-ABL positive leukemic cells
Oligonucleotide-based gene silencing, using molecules such as antisense oligonucleotides (ASOs), small interfering RNA, and aptamers, is widely...
-
The importance of personalized medicine in chronic myeloid leukemia management: a narrative review
BackgroundTyrosine kinase inhibitors (TKIs) are prescribed as a targeted therapy to treat chronic myeloid leukemia patients. A challenge in clinical...
-
Reversible follicular lymphoid hyperplasia related with dasatinib: first case report from Turkey
Chronic myeloid leukemia (CML) is a clonal hematopoietic stem cell disorder characterized by the presence of a cytogenetic abnormality, the...
-
Imatinib and Patient-Related Outcomes in Chronic Myeloid Leukemia: A Single Centric Experience
Imatinib is a signal transduction inhibitor useful in the management of chronic myeloid leukemia (CML). There is a dearth of evidence available...
-
Chronische myeloische Leukämie
BackgroundThe advent of tyrosine kinase inhibitors (TKI) has considerably improved prognosis and outcome of patients with chronic myelogenous...
-
Chronic myeloid leukemia: cytogenetics and molecular biology’s part in the comprehension and management of the pathology and treatment evolution
BackgroundChronic myelogenous leukemia (CML) is a type of blood cancer that affects hematopoietic stem cells and is often characterized by the...
-
Differential roles of STAT1 and STAT2 in the sensitivity of JAK2V617F- vs. BCR-ABL-positive cells to interferon alpha
BackgroundInterferon alpha (IFNa) monotherapy is recommended as the standard therapy in polycythemia vera (PV) but not in chronic myeloid leukemia...
-
Detection of mutations in CML patients resistant to tyrosine kinase inhibitor: imatinib mesylate therapy
Imatinib mesylate, a tyrosine kinase inhibitor, is the first choice in chronic myeloid leukemia treatment. However, resistance to imatinib may...
-
Targeting protein lysine methyltransferase G9A impairs self-renewal of chronic myelogenous leukemia stem cells via upregulation of SOX6
The application of tyrosine kinase inhibitors (TKIs) in clinic has revolutionized chronic myelogenous leukemia (CML) treatment, but fails to...
-
Twins with different personalities: STAT5B—but not STAT5A—has a key role in BCR/ABL-induced leukemia
Deregulation of the Janus kinase/signal transducers and activators of transcription (JAK/STAT) signaling pathway is found in cancer with STAT5A/B...
-
Control of Ph+ and additional chromosomal abnormalities in chronic myeloid leukemia by tyrosine kinase inhibitors
Chronic myeloid leukemia (CML) is a type of blood cancer that is known to affect hematopoietic stem cells. The presence of the Philadelphia...
-
Combating TKI resistance in CML by inhibiting the PI3K/Akt/mTOR pathway in combination with TKIs: a review
Chronic myeloid leukemia (CML), a myeloproliferative hematopoietic cancer, is caused by a genetic translocation between chromosomes 9 and 22. This...
-
Signal-transducing adapter protein-1 is required for maintenance of leukemic stem cells in CML
The family of signal-transducing adapter proteins (STAPs) has been reported to be involved in a variety of intracellular signaling pathways and...
-
Integrated systems biology analysis of acute lymphoblastic leukemia: unveiling molecular signatures and drug repurposing opportunities
Acute lymphoblastic leukemia (ALL) is a hematological malignancy characterized by aberrant proliferation and accumulation of lymphoid precursor cells...
